… Imiquimod is an immune response modifier commercially available as a 3.75 and 5%
cream. Topical imiquimod … on the mechanism of action of topical imiquimod, its FDA ‐approved …

… warts by imiquimod and ablative therapies. We summarise recent literature in this area
and propose combining imiquimod with other therapies to increase the efficacy of imiquimod. …

… Imiquimod (IMQ) ia an immunostimulating drug used for the … Imiquimod formulation and skin
delivery is highly challenging … Imiquimod skin retention from saturated solutions (Tween 80, …

… the existing information available on the use of imiquimod for BCC and comparing it to other
… , imiquimod has been shown to be an efficacious treatment modality for BCC. Imiquimod …

Since 2009, the imiquimod- or Aldara-induced (3M Pharmaceuticals, St. Paul, MN) model of
acute skin inflammation has become the most widely used mouse model in preclinical …

The pathology of psoriasis strongly depends on IL-17A. Monoclonal antibodies blocking
either the cytokine or its receptor are among the most efficient treatments for psoriatic patients. …

… The action of Imiquimod to stimulate innate immunity indicates its potential to treat viral
infections. We have clear evidence that Imiquimod is able to offer satisfactory stimulation of innate …

Background Imiquimod (IMQ) produces a cutaneous phenotype in mice frequently studied
as an acute model of human psoriasis. Whether this phenotype depends on strain or sex has …

Many autoimmune disorders such as psoriasis lead to the alteration of skin components
which generally manifests as unwanted topical symptoms. One of the most widely approved …

… This review summarises the available literature describing the use of topical imiquimod for
… to imiquimod which seem less effective than previously reported. Therefore, if imiquimod …